ArticleInternational dental journal2026
In Vitro Evaluation of Novel Resin-Modified Calcium Silicate Cements for Minimally Invasive Vital Pulp Therapy.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cytotoxicity and Bioactivity of Five Hydraulic Silicate Cements in Human Dental Pulp Cells at Different Setting Stages.International dental journal · 2026Article
- A regenerative strategy for vital pulp therapy: Platelet-rich fibrin augments stem cell viability and pluripotency in bioactive cement environments.Biochemistry and biophysics reports · 2026Article
- κ-Carrageenan-Based Hydrogels Support Viability and Odontogenic Differentiation of Stem Cells From the Apical Papilla.International dental journal · 2026Article
- Dose-dependent effects of Metformin on proliferation and odontogenic differentiation of dental pulp stem cells.BMC oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the biological effects of one conventional calcium silicate-based cement (MTA Angelus) and three resin-modified formulations (TheraCal PT, TheraBase Ca, and TheraCal LC) on human dental pulp stem cells (hDPSCs), focusing on cytocompatibility, cellular behaviour, and odontogenic/mineralization potential.
methodshDPSCs were cultured with material extracts at different dilutions (1:1, 1:2, 1:4). Cytocompatibility was assessed using MTT assay, wound-healing migration, and immunofluorescence for cytoskeletal organization. Cell adhesion and morphology were examined by SEM, while material composition was analysed by EDX. Odontogenic/osteogenic differentiation was evaluated through qRT-PCR for ALP, RUNX2, COL1A1, DSPP, BSP, and ON at 3 and 7 days, and extracellular matrix mineralization was quantified by Alizarin Red S staining at 21 days. Results were compared with untreated controls (P < .05).
resultsMTA Angelus exhibited the most favourable biological performance (***P < .001), with high cytocompatibility, strong upregulation of odontogenic genes, and abundant mineralized nodule formation. TheraCal PT showed intermediate outcomes, with higher gene expression and mineralization capacity than TheraBase Ca (***P < .001). TheraBase Ca provided the best cytocompatibility and cell adhesion among resin-modified cements (*P < .05) but induced moderate differentiation and mineralization. In contrast, TheraCal LC displayed the lowest cell viability, impaired migration, and limited mineralization potential (***P < .001).
conclusionMTA Angelus remains the benchmark material for vital pulp therapy due to its robust bioactivity, while TheraCal PT and TheraBase Ca emerge as promising resin-modified alternatives, each with distinct biological advantages. TheraCal LC, however, demonstrated limited cytocompatibility and regenerative potential. CLINICAL SIGNIFICANCE: These findings highlight the importance of material selection in vital pulp therapy. Resin-modified calcium silicate cements may serve as alternatives, but MTA Angelus continues to offer the most predictable biological outcomes for pulp preservation and repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.